GSK-3 inhibition overcomes chemoresistance in human breast cancer

Andrey Ugolkova,b,c, Irina Gaisind, Jin-San Zhang e, Daniel D. Billadeau e, Kevin White f, Alan Kozikowski d, Sarika Jains,h, Massimo Cristofanilli h,g, Francis Giles h,g, Thomas O’Halloran c, Vincent L. Crynsh, Andrew P. Mazar a,c,g,i,*

a Center for Developmental Therapeutics, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 2170 Campus Drive, Evanston, IL 60208, USA
b Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Galter Suite 3-150, 251 East Huron Street, Chicago, IL 60611, USA
c Department of Medicine, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, 1685 Highland Avenue, Madison, WI 53795, USA
d Chemistry of Life Processes Institute, Northwestern University, 2170 Campus Drive, Evanston, IL, 60208, USA
e Division of Oncology Research, Schulze Center for Novel Therapeutics, College of Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
f Institute of Genomics and Systems Biology, University of Chicago, 900 East 57th Street, KCBD 10100A, Chicago, IL 60637, USA
g Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Olson Pavilion, 233 East Superior Street, Chicago, IL 60611, USA
h Department of Medicine, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, 1685 Highland Avenue, Madison, WI 53795, USA
i Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Searle Building 8-510, 2170 Campus Drive, Evanston, IL 60208, USA

A B S T R A C T

Glycogen Synthase Kinase-3β (GSK-3β), a serine/threonine protein kinase, is an emerging therapeutic target in the treatment of human breast cancer. In this study, we demonstrate that the pharmacological inhibition of GSK-3 by two novel small molecule GSK-3 inhibitors, 9-ING-41 and 9-ING-87, reduced the viability of breast cancer cells but had little effect on non-tumorigenic cell growth. Moreover, treatment with 9-ING-41 enhanced the antitumor effect of irinotecan (CPT-11) against breast cancer cells in vitro. We next established two patient-derived xenograft tumor models (BC-1 and BC-2) from metastatic pleural effusions obtained from patients with progressive, chemorefractory breast cancer and demonstrated that 9-ING-41 also potentiated the effect of the chemotherapeutic drug CPT-11 in vivo, leading to regression of established BC-1 and BC-2 tumors in mice. Our results suggest that the inhibition of GSK-3 is a promising therapeutic approach to overcome chemoresistance in human breast cancer, and identify the GSK-3 inhibitor 9-ING-41 as a candidate targeted agent for metastatic breast cancer therapy.
indicators of poor prognosis and breast cancer patients with GSK-3β expression in the highest quartile (246 of 1686 cases) had a 2.7 and 1.7-fold increased risk of distant relapse 5 and 10 years after tumor resection, respectively [23]. A recent study demonstrated that GSK-3β knockdown significantly inhibited breast cancer cell proliferation whereas GSK-3α knockdown had only a minor effect in four breast cancer cell lines further credentialing GSK-3β as a viable therapeutic target for the treatment of breast cancer [24]. We recently identified two lead ATP-competitive GSK-3β inhibitors, 9-ING-41 and 9-ING-87, based on the potency of their antiproliferative activity against pancreatic and ovarian cancer cells in vitro as well as supportive ADMET and PK studies [13,25]. Here, we describe the anti-tumor activity of these novel inhibitors of GSK-3 in both breast cancer cell lines and in novel patient-derived xenograft (PDX) models of metastatic chemoresistant breast cancer. We conclude that the inhibition of GSK-3 is a promising therapeutic approach to overcome chemoresistance in metastatic breast cancer.

Materials and methods

Cell culture and reagents

Breast cancer cell lines MDA-MB-468, SKBR3 and MCF10A were obtained from American Type Culture Collection (ATCC, Manassas, VA); MDA-MB-231, UMCZ-4 breast cancer cell line was a gift from Drs. Giulio Francia (University of Texas–El Paso) and Robert Kerbel (Sunnybrook Research Institute). GSK-3 inhibitors 9-ING-41 and 9-ING-87 were synthesized in the laboratory of Dr. Kozikowski as previously described [13]. All other chemicals were obtained from Sigma (St. Louis, MO).

Measurement of cell viability

The relative number of viable cancer cells was determined by measuring the optical density using CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolum, inner salt; MTS] according to the manufacturer’s instructions (Promega, Madison, WI). GI50 value for each compound was calculated with a non-linear regression model of standard slope using GraphPad Prism 6.0 software (GraphPad, San Diego, CA).

Immunoblot analysis and antibodies

For immunoblots, cells were lysed and whole protein extract from cells was prepared as described previously [11]. Protein sample concentrations were determined by Bradford protein assay and equal amounts (50 μg) of protein were loaded in each well of SDS-polyacrylamide gel. Cell extracts were separated by 10% SDS-PAGE, transferred to PVDF membrane and probed as indicated. The following antibodies were used for immunoblot analysis: GSK-3β, phospho-Glycogen Synthase (Ser641), Bcl-2, PARP, X-linked inhibitor of apoptosis protein (XIAP), GAPDH (CellSignaling). Bound antibodies were detected as described previously [11].

Patient-derived xenograft (PDX) tumor models

The following research protocol was approved by Northwestern University institutional review board, and all patients provided appropriate informed consent. Metastatic pleural effusion samples were obtained from breast cancer patients and de-identified. Metastatic pleural effusion cells were engrafted into the mammary fat pad of non-obese diabetic/severe combined immunodeficient (NOD/SCID) gamma (NSG) mice (Jackson Laboratory). When a PDX tumor reached 1 cm in its largest dimension, the mouse was euthanized and freshly resected 2 mm × 2 mm tumor pieces were re-transplanted to NSG mice for in vivo studies. A piece of PDX tumor was fixed to PVDF membrane and probed as indicated. The following antibodies were used for immunoblot analysis: GSK-3β, phospho-Glycogen Synthase (Ser461), Bcl-2, PARP, X-linked inhibitor of apoptosis protein (XIP), GAPDH (Cell Signaling). Bound antibodies were detected as described previously [11].

Immunohistochemical staining

Immunohistochemical (IHC) staining was performed on paraffin sections of xenograft tumors. Paraffin sections were deparaffinized, and antigen retrieval was carried out in citric buffer in microwave for 10 min. The sections were incubated in 1% hydrogen peroxide for 10 minutes to quench endogenous tissue peroxidase. Tissue sections were then incubated with the anti-β-catenin (BD Biosciences, San Jose, CA), anti-GSK-3β or anti-phospho-Glycogen Synthase (Ser461) antibody (Cell Signaling, Danvers, MA) overnight at 4 °C. The slides were stained using a standard EnVision-System-HRP kit (DAKO, Carpinteria, CA) according to the manufacturer’s protocol. Immunohistochemical reactions were developed with diaminobenzidine as the chromogen peroxidase substrate, and slides were counterstained with hematoxylin. Negative control samples included replacement of the primary antibody with nonimmune IgG1 (DAKO).

Statistical analysis

All values are presented as mean ± SE. Cell viability assay and PDX tumor data were analyzed with one-way ANOVA. P values less than 0.05 are considered significant. Statistical analysis was performed using GraphPad Prism 6.0 software.

Results

Pharmacological inhibition of GSK-3 decreases viability of breast cancer cells

The two lead ATP-competitive GSK-3β inhibitors, 9-ING-41 and 9-ING-87, exhibit potent antiproliferative activity [13,25]. It should be noted that the two isoforms of GSK-3, α and β, are 98% homologous in the kinase domain and thus all known competitive inhibitors of GSK-3 inhibit both isoforms, and are thus referred to as GSK-3 inhibitors rather than GSK-3β inhibitors [13,26,27]. Compounds 9-ING-41 and 9-ING-87 are relatively selective for GSK-3 over ~320 other related kinases by at least one order of magnitude, including closely related serine/threonine kinases such as CDKs, PDKs, PKA, Akt, and PKCs [13]. Using immunoblotting, we found GSK-3β expression in three breast cancer cell lines and non-tumorigenic MCF10A cells (Fig. 1A). Next, we found that the inhibition of GSK-3 by 9-ING-41 and 9-ING-87 decreased MDA-MB-468 (ER−/HER2−) and SKBR3 (ER−/PR−/HER2+) breast cancer cell viability (Fig. 1B). Using immunoblotting, we found that the treatment of MDA-MB-468 and SKBR3 breast cancer cell lines with 9-ING-41 or 9-ING-87 resulted in inhibition of GSK-3 activity, as measured by the decreased expression of phospho-Glycogen Synthase, a downstream target of GSK-3 (Fig. 1C). We also found that the inhibition of GSK-3 resulted in a significant decrease in the expression of anti-apoptotic proteins Bcl-2 and XIAP and led to an induction of apoptosis in breast cancer cells as shown by PARP cleavage and Hoechst staining (Fig. 1C and D).

We then benchmarked 9-ING-41 and 9-ING-87 against the toolkit GSK-3 inhibitors AR-A014418 [26] and SB-216763 [27], as well as LY2093314 (developed by Eli Lilly) using a cell viability assay and found that the GI50 of 9-ING-41 and 9-ING-87 for inhibition of breast cancer cell growth is significantly lower than the GI50 of other GSK-3 inhibitors, including LY2090314 (Fig. 2A). To determine whether GSK-3 inhibitors affect non-transformed mammary epithelial cells, we treated MCF10A cells with several of the GSK-3 inhibitors (Fig. 2B). MCF10A are non-tumorigenic cells derived from benign proliferative breast tissue that were spontaneously immortalized and are suggested as a benign breast epithelial cell model [28]. We found that pharmacological inhibition of GSK-3 did not significantly affect the growth of MCF10A cells, whereas growth of SKBR3 and various breast cancer cell lines at the same concentrations was suppressed by the GSK-3 inhibitors AR-A014418, 9-ING-41 and 9-ING-87 (Figs. 1B and 2B). Taken together, our in vitro results support GSK-3 as a mediator of breast cancer cell survival, and identify 9-ING-41 as a candidate for the targeted treatment of human breast cancer.

GSK-3 inhibitor 9-ING-41 potentiates antitumor effect of conventional chemotherapeutic agents on breast cancer cell lines in vitro

We next tested our hypothesis that inhibition of GSK-3 may overcome resistance to the chemotherapeutic drug CPT-11 (irinotecan) using three distinct breast cancer cell lines. Traditional approaches for synergy analysis typically used with cytotoxic drugs are
difficult to apply to small molecule enzyme inhibitors such as 9-ING-41. Synergy analysis requires the evaluation of inhibition across a range of low to high concentrations of drugs. However, there is a minimal threshold (minimal effective concentration) of GSK-3 inhibition that must be achieved in order to see effects on breast cancer cell proliferation that prevents the observation of inhibition at concentrations of 9-ING-41 below the minimal effective concentration thereby impeding synergy analysis. Further, the prolonged continuous treatment (48–72 hours) of breast cancer cell lines typically used in synergy analysis leads to significant apoptosis using 9-ING-41 or 9-ING-87 as a single agent (Fig. 1C and D) or to a significant decrease of cell viability using cytotoxic agents (data not shown). Continuous exposure of cancer cell lines to the same concentration of drug for 72 hours is also not clinically translatable to a patient scenario, where tumor exposure is variable over time after drug administration as the drug is cleared. Therefore, we
modified our combination studies using pulses of drug exposure to breast cancer cell lines. Breast cancer cell lines were treated with 9-ING-41, CPT-11 or CPT-11 + 9-ING-41 for 3 hours. Post-treatment, cells were washed and all test compounds were replaced with fresh compound-free cell culture media. Breast cancer cells were then allowed to continue growing for 72 hours and relative cell growth was measured by a cell viability assay after 72 hours of growth. We compared the effect of 9-ING-41 on cell growth after 3 hour exposure to a 72 hour continuous exposure to compound (Fig. 2C). Varying responses were observed when breast cancer lines were exposed continuously for 72 hours to 9-ING-41 ranging from complete (e.g. MDA-MB-468) to partial (e.g. MDA-MB-231) inhibition of growth whereas only partial inhibition was observed across all three breast cancer cell lines tested after 3 hour exposure followed by washout (Fig. 2C). Based on the response of individual breast cancer cell line to 9-ING-41 treatment, we selected minimally effective concentration for 9-ING-41 of 0.25 μM, 0.5 μM and 2 μM for SKBR3, MDA-MB-468 and MDA-MB-231/LM2-4 breast cancer cell lines, respectively, for evaluation in combination experiments. Using the approach of short-term treatment (3 hours) to mimic transient drug exposure in vivo, we tested 9-ING-41 in combination with 1 μM and 10 μM of CPT-11 (Fig. 2D). CPT-11 at 10 μM exceeds the Cmax observed in patients when administered intravenously at a dose of 100 mg/m² [29], which approximates a clinically active dose. Using short-term treatment (3 hours), we demonstrated that 9-ING-41 potentiates the antitumor effects of 10 μM CPT-11 against MDA-MB-468...
Development and characterization of breast cancer patient-derived xenograft (PDX) models BC-1 and BC-2

We established two metastatic breast cancer PDX models, BC-1 and BC-2, by inoculating cells obtained from metastatic pleural effusions from breast cancer patients into NSG mice. BC-1 and BC-2 were derived from patients whose primary tumors were ER+/PR+/HER2- and maintained this molecular profile in PDX tumors as confirmed by immunohistochemical staining in serial passages in vivo. Usually, 17β-oestradiol pellet supplementation is required to grow ER-positive breast xenograft tumors in mice. However, we found that ER-positive BC-1 and BC-2 PDX tumors grew without 17β-oestradiol pellet supplementation in NSG mice. Although ESRI (the gene encoding the ER) mutations have not been found in treatment-naive human breast carcinomas, recently published studies identified ESRI mutations affecting the ligand-binding domain (LBD) of ER in advanced ER-positive hormone-resistant breast cancer, particularly in metastatic lesions from women who took estrogen-lowering drugs such as aromatase inhibitors [30,31]. The patients from whom BC-1 and BC-2 were derived were heavily pretreated and progressed through multiple cycles of treatment including aromatase inhibitors and DNA damaging drugs prior to developing metastatic pleural effusions (Figs. 3 and 4). DNA-sequencing results for the ESRI gene from the BC-1 PDX tumor revealed a Leu536Arg mutation in the ligand-binding domain of the ER whereas the BC-2 PDX tumor has a Tyr537Ser mutation. Although Leu536Arg mutation has not been previously reported, a Leu536Gln mutation in ER-α tumor has a Tyr537Ser mutation. Although the Leu536Arg mutation in the ligand-binding domain of the ER is currently being advanced through IND enabling a chemotherapeutic drug followed by washout with fresh drug-free cell culture media and then allowed the cells to grow for 72 hours. Under these conditions, we found that 9-ING-41 potentiates the effect of CPT-11 on breast cancer cell growth in vivo as the site of origin (metastatic pleural effusion) (Figs. 3 and 4). By immunohistochemical staining, we found that GSK-3β was expressed in BC-1 and BC-2 PDX tumors (Figs. 3E and 4E). We also found that expression of phosphorylated glycogen synthase (p-GS), a downstream target of GSK-3, was downregulated in 9-ING-41-treated BC-1 and BC-2 PDX tumors indicating target engagement in the PDX models (Figs. 3E and 4E). We found that β-catenin expression was not affected by the treatment with 9-ING-41 in BC-1 (loss of β-catenin expression) and BC-2 (β-catenin membranous staining) PDX tumors (Figs. 3E and 4E). Based on the broad enhancement of antitumor effects when 9-ING-41 is added to CPT-11 in breast cancer cell lines (Fig. 2D) and our observation that the patient tumors from which BC-1 and BC-2 were derived were highly chemoresistant in the clinic, we evaluated the ability of 9-ING-41 treatment to enhance tumor response in the breast cancer PDX models when combined with chemotherapy (CPT-11). Tumors in mice bearing orthotopic BC-1 or BC-2 were staged to approximately 200 mm³ prior to initiation of treatments and randomized to 4 treatment groups: control, 9-ING-41, CPT-11 and CPT-11 + 9-ING-41. Vehicle (DMSO) or drugs were injected intraperitoneally using the schedules indicated (Figs. 3 and 4). We found that CPT-11 or 9-ING-41 monotherapy did not significantly inhibit BC-1 PDX tumor growth, whereas combined CPT-11 and 9-ING-41 therapy led to regression of BC-1 tumors (Fig. 3). Statistical analysis of PDX tumor weight suggests that 9-ING-41 potentiates the effect of CPT-11 on the inhibition of BC-1 tumor growth, leading to tumor regression in the CPT-11 + 9-ING-41 group (P < 0.05) (Fig. 3C). In contrast to the completely chemoresistant BC-1 PDX tumors, which did not respond to either 9-ING-41 or CPT-11 monotherapy, we found that the growth of BC-2 PDX tumors was significantly inhibited by 9-ING-41 or CPT-11 monotherapy (Fig. 4B–D). However, similar to the BC-1 model, only the combination of 9-ING-41 and CPT-11 treatments led to tumor regression (P < 0.05) (Fig. 4B and C).

Discussion

Recently, GSK-3β has been credentialed as a potential therapeutic target in human breast cancer [23,24]. GSK-3β knockdown significantly inhibited breast cancer cell proliferation whereas GSK-3α knockdown had only a minor effect in four breast cancer cell lines, providing further support for GSK-3β as a breast cancer therapeutic target [24]. In a recently published study of 1686 cases of breast cancer, overexpression of GSK-3β was associated with several indicators of poor prognosis including lymph node metastasis, increased tumor size, high pathological grade, ER-negative disease, PR-negative disease, increased proliferation (measured by Ki-67) and HER2 overexpression [23]. Moreover, breast cancer patients with GSK-3β expression in the highest quartile (246 of 1686 cases) had a 2.7 and 1.7-fold increased risk of distant relapse 5 and 10 years after tumor resection, respectively [23]. In the present study, we describe a novel GSK-3 inhibitor 9-ING-41 which shows robust antitumor activity in vitro and in vivo and possesses drug-like properties [13,25,32]. Our in vitro results demonstrate that 9-ING-41 is a more potent inhibitor of breast cancer cell growth than other available GSK-3 inhibitors including the clinical stage compound LY2090314. We demonstrated that inhibition of GSK-3 by 9-ING-41 decreases the survival of breast cancer cells in vitro, consistent with previously published studies in other tumor cell types [11–22,25,32–36]. Our previous studies in leukemic cells showed that the inhibition of GSK-3 using a toolkit inhibitor suppressed NF-kB transcriptional activity and decreased the expression of the antiapoptotic proteins (XIAP, Bcl-2), leading to enhanced cancer cell apoptosis [15]. Given that NF-kB-mediated chemoresistance has been shown to be a major driver of breast cancer progression [37,38], we examined inhibition of GSK-3 by 9-ING-41 in breast cancer cells in vitro and found it decreased the expression of anti-apoptotic molecules NF-kB target genes Bcl-2 and XIAP inducing apoptosis. We then tested whether 9-ING-41 could enhance the response of the chemoresistant metastatic breast cancer cell lines to the chemotherapeutic drug CPT-11 in vitro. Chemoresistance of cancer cells in vitro is defined by many factors including drug concentration and duration of exposure in cell culture. Because continuous exposure (72–96 hours) of breast cancer cells to either 9-ING-41 or a chemotherapeutic drug significantly suppresses cell viability and does not mimic tumor exposure to a drug in vivo, we carried out short term (3 hours) exposures of breast cancer cell lines using a minimal effective inhibitory concentration of 9-ING-41 in combination with a chemotherapeutic drug followed by washout with fresh drug-free cell culture media and then allowed the cells to grow for 72 hours. Under these conditions, we found that 9-ING-41 potentiates the antitumor effects of CPT-11 on breast cancer cell growth. Our in vitro results suggested that inhibition of GSK-3 by 9-ING-41 buffers these treatments from such effects and provides a new opportunity for therapeutic intervention in breast cancer patients.
sensitized metastatic breast cancer cells to CPT-11 chemotherapy, a potent drug that has otherwise limited clinical activity in this indication.

A number of in vivo studies have investigated the antitumor activity of distinct GSK-3 inhibitors in a variety of cancer cell line-derived tumor xenograft models [14,21,22,24,33,39,40]. These studies utilized tool kit GSK-3 inhibitors as monotherapies. Although inhibition of tumor growth was reported, the antitumor effects were modest and the compounds used in these studies were not amenable for clinical development. In order to evaluate 9-ING-41 in combination with chemotherapy in vivo, we established two PDX models of metastatic breast cancer, BC-1 and BC-2, using metastatic pleural effusion cells obtained from breast cancer patients who had failed multiple cycles of treatment in the clinic. PDX tumor models have emerged as a promising approach to evaluate the effects of cancer drugs on patient tumors and provide a new tool for evaluating new oncology drug candidates under development [41]. Comparison of tumors from patients and corresponding PDX tumors have demonstrated consistency in histological appearance, growth, mutations and gene expression patterns when PDX models are passaged in vivo [41–43]. This preservation of molecular and histological characteristics in PDX models suggests that PDX models may be...
superior to traditional cell line xenografts and better predictive of treatment response of novel anticancer drugs, a hypothesis that has gained strong support from a recently published high throughput drug evaluation study using PDX models [41]. Although we found that BC-1 and BC-2 PDX tumors express ER, surprisingly, these tumors grow without estradiol supplementation in immunodeficient mice. We found that both of these PDX tumors carry activating mutations in ESR1 which confer ligand-independent activity to ER and make them resistant to tamoxifen and fulvestrant treatment [30,31]. These mechanistic insights are consistent with the clinical course and responses of the BC-1 and BC-2 patient donors. We found that treatment with the combination of CPT-11 and 9-ING-41, in contrast to either agent used alone, led to regression of established BC-1 tumors. These data are consistent with results of the in vitro studies showing that 9-ING-41 potentiates the antitumor effect of CPT-11 in breast cancer cells after short-term exposure. In contrast to CPT-11-resistant BC-1 PDX tumors, which were also resistant to 9-ING-41 monotherapy at the dose and schedule evaluated in vivo, we found that the growth of BC-2 PDX tumors was partially inhibited by either 9-ING-41 or CPT-11 monotherapy. Tumor regressions were only observed in the BC-1 and BC-2 PDX models when 9-ING-41 and CPT-11 were used in combination. Thus, our in vivo results provide a rationale for combining 9-ING-41 and CPT-11 as a novel therapeutic approach for the treatment of metastatic breast cancer.

Fig. 4. Treatment with CPT-11 + 9-ING-41 leads to a regression of breast BC-2 PDX (ER+/PR+/HER2−) tumors. (A) Treatment history of breast cancer patient (case BC-2). Breast PDX tumor model was established after orthotopic injection of metastatic pleural effusion cells (obtained from breast cancer patient) in NSG mouse. Breast PDX tumor pieces were re-transplanted orthotopically to 16 mice (1 tumor per mouse). Tumors were size matched and mice were randomized into 4 treatment groups: control (DMSO; n = 4 mice), CPT-11 (20 mg/kg, n = 4 mice), 9-ING-41 (70 mg/kg, n = 4 mice) and CPT-11 + 9-ING-41 (n = 4 mice). (B) Vehicle or drugs were injected as indicated by arrows. Points, mean tumor volume; bars, SE. (C) Weight of resected tumors was measured. Columns, mean tumor weight; bars, SE. (D) Representative pictures of PDX subQ tumors from each group of animals. (E) Representative pictures of GSK-3β, phospho-Glycogen Synthase and β-catenin expression in control and 9-ING-41-treated BC-2 PDX tumors.
breast cancer as well as exploring additional combinations of 9-ING-41 with chemotherapy more extensively in metastatic breast cancer PDX tumor models as part of future pre-clinical development. The GS3-3 inhibitor 9-ING-41 is now being advanced as a clinical candidate and a recently completed pre-IND meeting has helped to elucidate an IND enabling development plan for 9-ING-41, with an IND submission anticipated in early 2017. Taken together, our findings provide critical evidence that inhibition of GS3-3 may be a promising therapeutic approach to overcome chemoresistance in metastatic breast cancer and provide the first rationale for the clinical development of 9-ING-41 in this indication.

Acknowledgments

This study was supported by a generous donation from the Baskes Family to the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and by Cancer Center Support Grant 2 P30 CA060553-19 (APM, AU) to the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. We thank Jian-Jun Wei, Jeremy Mathews, Demirkar Gursel, Stephen Rohan, Bernice Frederick and Bella Shmaltsuyev (Pathology Core Facility, Robert H. Lurie Comprehensive Cancer Center, Northwestern University) and Gennady Bondarenko (Center for Developmental Therapeutics, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Evanston, IL) for providing us clinical samples of breast cancer and technical assistance. We express our gratitude to Jody Hirsh for editorial assistance.

Conflict of interest

9-ING-41 has been licensed to Actuate Therapeutics, Inc. Alan Kozikowski, Andrey Ugolkov, Thomas O’Halloran and Andrew Mazar hold an equity interest in Actuate Therapeutics, Inc. Alan Kozikowski and Irina Gaisina are inventors on the 9-ING-41 patent.

References


